Report
Richard Williamson

EMIS Group - Balancing the near- and long-term view

EMIS reported respectable results for H120 considering the uncertainty in the NHS and COVID-19 restrictions. The company expects to meet consensus estimates for FY20 and announced an interim dividend of 16p (+3% y o y). We have made minor changes to forecasts. Work on the product roadmap is ongoing with the first new data analytics product due in Q4. In our view, the rapid shift to digital working during the pandemic supports and potentially accelerates the adoption of technology within healthcare in the longer term.
Underlying
EMIS Group

EMIS Group is engaged in connected healthcare software and services. Co. provides healthcare software, information technology and related services in the U.K. Co.'s brands include: EMIS Health, which provides clinical software; EMIS Care, which deliver diabetic retinopathy eye screening; Patient.info, an independent online health platform; and Egton, which provides non-clinical products and services as well as software to the social care sector. Co. has three operating segments, all of which involved with the supply and support of connected healthcare software and services: Primary & Community Care; Community Pharmacy; and Secondary & Specialist Care.

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Analysts
Richard Williamson

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch